SCHEMBL973113

SCHEMBL973113

CCOC(=O)c1cc(CC)nn1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
RAB9A P51151 4/20 0.49
SMN1; SMN2 Q16637 4/20 0.49
NPC1 O15118 3/20 0.49
MAPT P10636 1/20 0.49
KDM4E B2RXH2 2/20 0.47
SMYD3 Q9H7B4 1/20 0.47
NAMPT P43490 1/20 0.46
POLB P06746 2/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
FAAH O00519 2/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
TDP1 Q9NUW8 2/20 0.42
ALDH1A1 P00352 2/20 0.40
HPGD P15428 1/20 0.40
MAPK1 P28482 1/20 0.40
CLK1 P49759 1/20 0.40
UBE2N P61088 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7699075 0.89 LMNA (0.49) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL859 0.87 POLB (0.50) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL5900613 0.87 LMNA (0.48) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL7703155 0.86 LMNA (0.47) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL9199202 0.85 SMYD3 (0.51) RAB9ASMN1; SMN2NPC1MAPTKDM4E
SCHEMBL14109576 0.83 LMNA (0.45) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL1894879 0.83 LMNA (0.52) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL20503314 0.82 LMNA (0.44) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL6713457 0.82 LMNA (0.44) LMNARAB9ASMN1; SMN2NPC1MAPT
SCHEMBL7698241 0.81 LMNA (0.61) LMNARAB9ASMN1; SMN2NPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-106187894-A The preparation method of 1 methyl 3 ethyl 4 chlorine 5 pyrazole carboxylic acid ethyl ester 潍坊鑫诺化工有限公司 2016-12-07 CN claimed
CN-103556174-A Synthesis method of ethyl 4-chloro-1-methyl-3-ethyl-5-pyrazolylcarboxylate UNIV HARBIN SCIENCE & TECH 2014-02-05 CN claimed
CN-103508959-A Synthesis method of 1-methyl-3-ethyl-5-pyrazolyl ethyl carboxylate UNIV HARBIN SCIENCE & TECH 2014-01-15 CN claimed
CN-103102307-A Method for synthesizing tolfenpyrad UNIV HEILONGJIANG 2013-05-15 CN claimed
US-20260070924-A1 INDAZOLE MACROCYCLES AND THEIR USE BLOSSOMHILL THERAPEUTICS INC (US) 2026-03-12 US disclosed
CN-121204042-A Method for preparing pesticide intermediate by catalyzing multienzyme and coenzyme co-immobilized nanogel 南京科力硕生物科技有限公司 2025-12-26 CN disclosed
US-20250143305-A1 PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT MITSUI CHEMICALS CROP & LIFE SOLUTIONS, INC. (JP) 2025-05-08 US disclosed
EP-4536225-A1 INDAZOLE MACROCYCLES AND THEIR USE Blossomhill Therapeutics, Inc. (US) 2025-04-16 EP disclosed
WO-2025049827-A1 FRAGRANCE AND FLAVOR COMPOSITIONS COMPRISING PYRAZOLE DERIVATIVES OSMO LABS, PBC (US) 2025-03-06 WO disclosed
CN-119421709-A Indazole-containing macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-02-11 CN disclosed
CN-116063285-B Substituted pyrimidine (thio) ester compound and application thereof 沈阳中化农药化工研发有限公司 2025-02-11 CN disclosed
CN-119325379-A Indazole macrocyclic compounds and uses thereof 荣山医药股份有限公司 2025-01-17 CN disclosed
US-20130023517-A1 Therapeutic methods employing substituted piperidines which are CCR3 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-24 US disclosed
US-20110015065-A1 Substituted Sulfonic Acid Amide Compounds BASF SE (DE) 2011-01-20 US disclosed
EP-2252590-A1 SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS BASF SE (DE) 2010-11-24 EP disclosed
WO-2009101082-A1 SUBSTITUTED SULFONIC ACID AMIDE COMPOUNDS BASF SE (DE) 2009-08-20 WO disclosed
US-20070010402-A1 Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof NIHON NOHYAKU CO., LTD., (JP) 2007-01-11 US disclosed
US-20070010402-A1 Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof NIHON NOHYAKU CO., LTD., (JP) 2007-01-11 US disclosed
US-20070010402-A1 Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof NIHON NOHYAKU CO., LTD., (JP) 2007-01-11 US disclosed
EP-1544202-A1 NOVEL HERBICIDES, USAGE THEREOF, NOVEL THIENOPYRIMIDINE DERIVATIVES, INTERMEDIATES OF THE SAME, AND PROCESS FOR PRODUCTION THEREOF Nihon Nohyaku Co., Ltd. (JP) 2005-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110015065-A1 Substituted Sulfonic Acid Amide Compounds STS, NAPA, NAAA LMNA 3828/4885RAB9A 655/4885SMN1; SMN2 3963/4885
US-20260070924-A1 INDAZOLE MACROCYCLES AND THEIR USE NR0B2, NR0B1, ESRRA LMNA 1639/4885RAB9A 1995/4885SMN1; SMN2 1266/4885
US-20070010402-A1 Novel herbicides, usage thereof, novel thienopyrimidine derivatives, intermediates of the same, and process for production thereof DDT, DPYD, DHODH LMNA 4855/4885RAB9A 4004/4885SMN1; SMN2 4244/4885
US-20250143305-A1 PYRAZOLE COMPOUND AND PEST CONTROL AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT HDAC11, AADAC, CTRL LMNA 4541/4885RAB9A 399/4885SMN1; SMN2 3563/4885
US-20130023517-A1 Therapeutic methods employing substituted piperidines which are CCR3 antagonists CCR3, CCR1, CCR4 LMNA 4598/4885RAB9A 1934/4885SMN1; SMN2 1205/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.